Literature DB >> 25806315

Minimal requirements for the molecular testing of lung cancer.

Helmut H Popper1, József Tímár1, Ales Ryska1, Wlodzimierz Olszewski1.   

Abstract

From the aspect of the contemporary pathologic diagnostics of lung cancer, it is a key issue of the tissue obtained since small biopsies and cytology still play a major role. In the non-small cell lung cancer era, cytology considered equal to biopsy. However, in recent years it is unable to provide quality diagnosis and must be replaced by biopsy. Various molecular techniques can handle various different tissue samples which must be considered during molecular pathology diagnosis. Besides, tumor cell-normal cell ratio in the obtained tissue as well as the absolute tumor cell number have great significance whose information must be provided in the primary lung cancer diagnosis. Last but not least, for continuous sustainable molecular diagnostics of lung cancer rational algorythms, affordable technology and appropriate reimbursement are equally necessary.

Entities:  

Keywords:  Lung cancer; molecular testing; requirements

Year:  2014        PMID: 25806315      PMCID: PMC4367742          DOI: 10.3978/j.issn.2218-6751.2014.10.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  5 in total

Review 1.  Personalized medicine for lung cancer: new challenges for pathology.

Authors:  Keith M Kerr
Journal:  Histopathology       Date:  2011-09-14       Impact factor: 5.087

Review 2.  The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.

Authors:  Erik Thunnissen; Keith M Kerr; Felix J F Herth; Sylvie Lantuejoul; Mauro Papotti; Robert C Rintoul; Giulio Rossi; Birgit G Skov; Birgit Weynand; Lukas Bubendorf; Grünberg Katrien; Leif Johansson; Fernando López-Ríos; Vincent Ninane; Włodzimierz Olszewski; Helmut Popper; Sauleda Jaume; Philipp Schnabel; Luc Thiberville; Florian Laenger
Journal:  Lung Cancer       Date:  2011-12-03       Impact factor: 5.705

Review 3.  Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

Authors:  David A Eberhard; Giuseppe Giaccone; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

4.  Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.

Authors:  Oana C Rafael; Mohamed Aziz; Harry Raftopoulos; Oana E Vele; Weisheng Xu; Chiara Sugrue
Journal:  Cancer Cytopathol       Date:  2014-04-10       Impact factor: 5.284

5.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2013-04-04       Impact factor: 5.568

  5 in total
  6 in total

1.  Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies.

Authors:  Sinchita Roy-Chowdhuri; Hui Chen; Rajesh R Singh; Savitri Krishnamurthy; Keyur P Patel; Mark J Routbort; Jawad Manekia; Bedia A Barkoh; Hui Yao; Sharjeel Sabir; Russell R Broaddus; L Jeffrey Medeiros; Gregg Staerkel; John Stewart; Rajyalakshmi Luthra
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

Review 2.  Small cell lung cancer (SCLC): no treatment advances in recent years.

Authors:  Filippos Koinis; Athanasios Kotsakis; Vasileios Georgoulias
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 3.  Genetic Markers in Lung Cancer Diagnosis: A Review.

Authors:  Katarzyna Wadowska; Iwona Bil-Lula; Łukasz Trembecki; Mariola Śliwińska-Mossoń
Journal:  Int J Mol Sci       Date:  2020-06-27       Impact factor: 5.923

4.  Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.

Authors:  Martijn J H G Simons; Valesca P Retèl; Bram L T Ramaekers; Rogier Butter; Joanne M Mankor; Marthe S Paats; Joachim G J V Aerts; Zakile A Mfumbilwa; Paul Roepman; Veerle M H Coupé; Carin A Uyl-de Groot; Wim H van Harten; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2021-08-18       Impact factor: 4.981

5.  Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia.

Authors:  Herbert H Loong; Carlos K H Wong; Catherine P K Chan; Andrea Chang; Zheng-Yi Zhou; Wenxi Tang; Meaghan Gibbs
Journal:  JTO Clin Res Rep       Date:  2022-02-14

6.  Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.

Authors:  Kelly Dufraing; J Henricus van Krieken; Gert De Hertogh; Gerald Hoefler; Anca Oniscu; Tine P Kuhlmann; Wilko Weichert; Caterina Marchiò; Ari Ristimäki; Aleš Ryška; Jean-Yves Scoazec; Elisabeth Dequeker
Journal:  Histopathology       Date:  2019-07-18       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.